Autotoxicity, methylation and a road to the prevention of Parkinson's disease

Journal of Clinical Neuroscience

Volumn 12, Issue 1, 2005, Pages 6-11

  Williams, Adrian C ^a,b   Ramsden, David B ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

autotoxicity; NAD; nicotinamide; NNMT; Parkinson's disease; xenobiotics

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CAFFEINE; DECARBOXYLASE INHIBITOR; DOPAMINE; ENZYME INHIBITOR; N METHYLNICOTINAMIDE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINE; NUCLEOTIDE; PYRIDINE; S ADENOSYLMETHIONINE; XENOBIOTIC AGENT;

BLOOD BRAIN BARRIER; DIET; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; GENETICS; HUMAN; METHYLATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 11444250619     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2004.10.002     Document Type: Short Survey

References (79)

1. A.C. Williams Ecogenetics, xenobiotic biochemistry and neurological disease J Neurol 238 1991 187 190
2. A.C. Williams Hypersusceptibility to chemicals: risk factors for neurological disease? J Neurol Neurosurg Psychiatry 56 1993 943 946
3. A.C. Williams Susceptibility to neurotoxins D.B. Calne Neurodegenerative diseases 1993 205 224
4. G.S. Roth, D.K. Ingram, and M.A. Lane Caloric restriction in primates and relevance to humans Ann NY Acad Sci 928 2001 305 315
5. G.C. Davies, A.C. Williams, and S.P. Markey Chronic parkinsonism secondary to intravenous injection of meperidine analogues Psychiat Res 1 1979 249 254
6. J.W. Langston, P. Ballard, J.W. Tetrud, and I. Irwin Chronic parkinsonism in humans due to a product of meperidine-analog synthesis Science 219 1983 979 980
7. K. Chiba, A. Trevor, and N. Castagnoli Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase Biochem Biophys Res Commun 120 1984 574 578
8. J.A. Javitch, R.J. D'Amato, S.M. Strittmatter, and S.H. Snyder Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity Proc Natl Acad Sci USA 82 1985 2173 2177
9. R.R. Ramsey, and T.P. Singer Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine, by mitochondria J Biol Chem 261 1986 7585 7587
10. W.J. Nicklas, I. Vyas, and R.E. Heikkila Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine Life Sci 36 1985 2503 2508
11. D. Di Monte The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2 2003 531 536
12. R. Betarbet, T.B. Sherer, G. MacKenzie, M. Garcia-Osuna, A.V. Panov, and J.T. Greenamyre Chronic systematic pesticide exposure reproduces features of Parkinson's disease Nat Neurosci 3 2000 1301 1306
13. A. Menegon, P.G. Board, A.C. Blackburn, G.D. Mellick, and D.G. Le Couteur Parkinson's disease, pesticides, and glutathione transferase polymorphisms Lancet 352 1998 1344 1346
14. A.J. Bradbury, B. Costall, and A.M. Domeney The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking the N-methyl moiety Neurosci Lett 61 1985 121 126
15. M.A. Collins, E.J. Neafsey, K. Matsubara, R.J. Cobuzzi Jr., and H. Rollema Indole-N-methylated β-carbolinium ions as potential brain-bioactivated neurotoxins Brain Res 570 1992 154 160
16. Y. Kotake, Y. Tasaki, Y. Makino, S. Ohta, and M. Hirobe 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF J Neurochem 65 1995 2633 2638
17. Y. Maruyama, T. Abe, H. Tohgi, P. Dostert, and M. Naoi A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in parkinsonian cerebrospinal fluid Ann Neurol 40 1996 119 122
18. K. Matsubara, S. Kobayashi, and Y. Kobayashi β-Carbolinium cations, endogenous MPP+ analogs, in the lumber cerebrospinal fluid of parkinsonian patients Neurology 45 1995 2240 2245
19. T. Nagatsu Isoquinoline neurotoxins in the brain and Parkinson's disease Neurosci Res 29 1997 99 111
20. T. Nagatsu, and M. Yoshida An endogenous substrate of brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions Neurosci Lett 87 1988 178 182
21. M. Naoi, S. Matsuura, T. Takahashi, and T. Nagatsu A N-methyl-transferase in human brain catalyses N-methylation of 1,2,3,4-tetrahydroisoquinoline, a precursor of a dopaminergic neurotoxin, N-methylisoquinolinium ion Biochem Biophys Res Commun 161 1989 1213 1219
22. M. Naoi, P. Dostert, M. Yoshida, and T. Nagatsu N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins Adv Neurol 60 1993 212 217
23. M. Naoi, W. Maruyama, T. Niwa, and T. Nagatsu Novel toxins and Parkinson's disease: N-methylation and oxidation as metabolic bioactivation of neurotoxin J Neural Transm 41 Suppl 1994 197 205
24. M. Naoi, W. Maruyama, N. Nakao, T. Ibi, K. Sahashi, and M.S. Benedetti (R)-Salsolinol N-methyltransferase activity increases in parkinsonian lymphocytes Ann Neurol 43 1998 212 216
25. K. Akoyama, K. Matsubara, and M. Kondo Nicotinamide N-methyl-transferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease Neurosci Lett 298 2001 78 80
26. A.H. Schapira, V.M. Mann, and J.M. Cooper Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease J Neurochem 55 1990 2142 2145
27. S.S. Ansher, J.L. Cadet, W.B. Jakoby, and J.K. Baker Role of N-methyl-transferases in the neurotoxicity associated with the metabolites of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and other 4-substituted pyridines in the environment Biochem Pharmacol 35 1986 3359 3363
28. K. Maise, and Z.Z. Chong Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain Trend Pharmacol Sci 24 2003 228 230
29. M.F. Beal Bioenergetic approaches for neuroprotection in Parkinson's disease Ann Neurol 53 Suppl 3 2003 39 47
30. Cartwright L, Williams AC, Ramsden DB. Nicotinamide: neuroprotective effects against dopamine and MPP+. In: Proceedings of the Global College of Neuroprotection and Neuroregeneration, Annual Conference 2004, Zermatt
31. S. Green, S. Buttrum, and H. Molloy N-methylation of pyridines in Parkinson's disease Lancet 338 1991 120 121
32. A. Williams, S. Sturman, G. Steventon, and R. Waring Metabolic biomarkers of Parkinson's disease Acta Neurol Scand 84 Suppl 136 1991 19 23
33. A. Williams, and R. Waring The MPTP tale: pathway to prevention of Parkinson's disease? Br J Hosp Med 49 1993 716 719
34. K. Aoyama, K. Matsubara, and K. Okada N-Methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test J Neural Transm 107 2000 985 995
35. J. Willets, J. Lunec, A.C. Williams, and H.R. Griffiths Neurotoxicity of nicotinamide derivatives; their role in the aetiology of Parkinson's disease Biochem Soc Transact 21 1993 299S
36. T. Fukushima, A. Kaetsu, H. Lim, and M. Moriyama Possible role of 1-methylnicotinamide in the pathogenesis of Parkinson's disease Exp Toxic Pathol 53 2002 469 473
37. T. Fukushima, T. Tawara, A. Isobe, N. Hojo, K. Shiwaku, and Y. Yumane Radical formation site of cerebral complex 1 and Parkinson's disease J Neurosci Res 42 1995 385 390
38. R. Spector Niacin and niacinamide transport in the central nervous system. In vivo studies J Neurochem 33 1979 895 904
39. M. Gerlach, E. Koutsilieri, and P. Riederer N-methyl-(R)-salsolinol and its relevance to Parkinson's disease Lancet 351 1998 850 851
40. A.C. Williams, M.-.L. Smith, R.H. Waring, and D.B. Ramsden The aetiology of idiopathic Parkinson's disease: a genetic and environmental model Adv Neurol 80 1999 215 218
41. D.B. Ramsden, R.B. Parsons, S.-.L. Ho, T. Xie, R.H. Waring, and A.C. Williams Further studies in xenobiotic metabolism and Parkinson's disease Adv Neurol 86 2001 105 113
42. R.B. Parsons, M.-.L. Smith, A.C. Williams, R.H. Waring, and D.B. Ramsden Expression of nicotinamide N-methyltransferase (E.C. 2.1.1.1) in the Parkinsonian brain J Neuropathol Exp Neurol 61 2002 111 124
43. R.B. Parsons, S.W. Smith, R.H. Waring, A.C. Williams, and D.B. Ramsden High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease Neurosci Lett 342 2003 13 16
44. H.S. Pall, R. Surtees, S.G. Sturman, A. Powell, and A.C. Williams S-adenosylmethionine in cerebrospinal fluid in Parkinson's disease (Abstract) Neurology 42 Suppl 3 1992 283
45. T. Müller, D. Woitalla, B. Hauptmann, B. Fowler, and W. Kuhn Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease Neurosci Lett 308 2001 54 56
46. C.G. Charlton, and B. Crowell Jr. Striatal dopamine depletion, tremors, and hypokinesia following the intracranial injection of S-adenosylmethionine: a possible role of hypermethylation in Parkinsonism Mol Chem Neuropathol 26 1995 269 283
47. R.M. Weinshilboum, D.M. Otterness, and C.L. Szumlanski Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase Annu Rev Pharmacol Toxicol 39 1999 19 52
48. M.-.L. Smith, D. Burnett, and P. Bennett A direct correlation between nicotinamide N-methyltransferase activity and protein levels in the human liver cytosol Biochem Biophys Acta 1422 1998 238 244
49. G.W. Ross, R.D. Abbott, and H. Petrovitch Association of coffee and caffeine intake with the risk of Parkinson's disease JAMA 283 2000 2674 2679
50. A. Ascherio, S.M. Zhang, and M.A. Hernan Prospective study of caffeine consumption and risk of Parkinson's disease in men and women Ann Neurol 50 2001 56 63
51. M. Sugita, T. Izuno, M. Tatemichi, and Y. Otahara Meta-analysis for epidemiologic studies on the relationship between smoking and Parkinson's disease J Epidemiol 11 2001 87 94
52. D.M. Morens, A. Grandinetti, D. Reed, L.R. White, and G.W. Ross Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 45 1995 1041 1051
53. J.M. Gorell, B.A. Rybicki, C.C. Johnson, and E.L. Peterson Smoking and Parkinson's disease: a dose-response relationship Neurology 52 1999 115 119
54. C.M. Tanner, S.M. Goldman, and D.A. Aston Smoking and Parkinson's disease in twins Neurology 58 2002 581 588
55. G.W. Ross, R.D. Abbott, and H. Petrovitch Association of coffee and caffeine intake with the risk of Parkinson disease JAMA 283 2000 2674 2679
56. M.D. Benedetti, J.H. Bower, and D.M. Maraganore Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study Neurology 55 2000 1350 1358
57. W. Hellenbrand, H. Boeing, and B.-.P. Robra Diet and Parkinson's disease II: a possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study Neurology 47 1996 644 650
58. P.-.A. Fall, M. Fredrikson, O. Axelson, and A.-.K. Granérus Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden Movement Disord 14 1999 28 37
59. Z.-.H. Zhang, and G.C. Román Worldwide occurrence of Parkinson's disease: an updated review Neuroepidemiol 12 1993 195 208
60. M. Baldereschi, A. Di Carlo, and W.A. Rocca Parkinson's disease and parkinsonism in a longitudinal study: twofold higher incidence in men. ILSA working group. Italian Longitudinal Study on Ageing Neurology 55 2000 1358 1363
61. M.H. Polymeropoulos, C. Lavedan, and E. Leroy Mutation in the α-synuclein gene identified in families with Parkinson's disease Science 276 1997 2045 2047
62. E.K. Tan, C. Tan, and H. Shen α-Synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability Neurosci Lett 336 2003 70 72
63. T. Kitada, S. Asakawa, and N. Hattori Mutations in the Parkin gene causes autosomal recessive juvenile parkinsonism Nature 392 1998 605 608
64. V. Bonifati, P. Rizzu, and M.J. van Baren Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism Science 299 2003 256 259
65. D.M. Maraganore, M.J. Farrer, J.A. Hardy, S.J. Lincoln, S.K. McDonnell, and W.A. Rocca Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease Neurology 53 1999 1858 1860
66. E. Leroy, R. Boyer, and G. Auburger The ubiquitin pathway in Parkinson's disease Nature 395 1998 451 452
67. J. Hardy, M.R. Cookson, and A. Singleton Genes and parkinsonism Lancet Neurol 2 2003 221 228
68. E.M. Valente, P.M. Abou-Sleiman, and V. Caputo Hereditary Early-onset Parkinson's disease caused by mutations in PINK1 Science 304 2004 1158 1160
69. W. Dauer, N. Kholodilov, and M. Vila Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP Proc Natl Acad Sci USA 99 2002 14524 14529
70. M. Vila, S. Vukosavic, V. Jackson-Lewis, M. Neystat, M. Jakowerc, and S. Przedborski α-Synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP J Neurochem 74 2000 721 729
71. M. Naoi, W. Maruyama, P. Dostert, and Y. Hashizume N-methyl-(R)- salsolinol as a dopaminergic neurotoxin: from an animal model to an early marker of Parkinson's disease J Neural Transm 50 Suppl 1997 89 105
72. J.D. Spillane Pellagra In Nutritional Disorders of the Nervous System 1947 E&S Livingstone Edinburgh 29-47
73. R.H. Waring, S.G. Sturman, M.C.G. Smith, G.B. Steventon, M.T.E. Heafield, and A.C. Williams S-methylation in motor neuron disease and Parkinson's disease Lancet 2 8659 1989 356 357
74. L. Peters, G.B. Steventon, S. Green, S. Sturman, R.H. Waring, and A.C. Williams D-Penicillamine metabolism in neurodegenerative diseases: an in vivo/in vitro sulphydryl methylation study Xenobiotica 24 1994 1013 1020
75. F. Kamel, D.M. Umbach, and T.L. Munsat Lead exposure and amyotrophic lateral sclerosis Epidemiol 13 2002 311 319
76. R.H. Brown Jr., and W. Robberecht Amyotrophic lateral sclerosis: pathogenesis Semin Neurol 21 2001 131 139
77. G.E. Kisby, M. Ellison, and P.S. Spencer Content of the neurotoxins cycasin (methylazoxymethanol β-D-glucoside) and BMAA (β-N-methylamino- L-alanine) in cycad flour prepared by Guam Chamorros Neurology 42 1992 1336 1341
78. H. Matsumoto, and H.H. Higa Studies on methylazoxymethanol, the aglycone of cycasin: methylation of nucleic acids in vitro Biochem J 98 1996 20c
79. Kisby GE, Nottingham V, Kaytor R. Brain metabolism of β-N-methylamino-L-alanine (BMAA) and protection of excito-toxicity by GABA uptake inhibitors (Abstract). In: Proceedings of the Society of Neuroscience Annual Meeting. Abstract 18.82; 1992